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Abstract
Purpose This study seeks to characterize magnetic reso-
nance imaging (MRI) changes following stereotactic
radiosurgery (SRS) of pediatric brain malignancies.
Methods Serial MRI evaluations were performed on 21
lesions treated with SRS for either medulloblastoma (n=12),
juvenile pilocytic astrocytoma (n=4), ependymoma (n=2),
atypical rhabdoid teratoid tumor (n=2), or pineocytoma
(n=1). Prescription doses ranged from 14 to 30 Gy in one
to five fractions. Tumor response was qualified as
complete (CR), partial (PR), stable disease (SD), or
progressive disease (PD) according to the RECIST v1.1.
Median radiographic follow-up after SRS was 17 months.
Results A total of 80 follow-up MRI scans were reviewed
with a median of eight per patient. During serial MRI
evaluation, eight lesions met criteria for PD at a median of
6 months. However, of these, three (37%) represented
transient tumor edema with two lesions later developing a
CR at a median of 15 months and one persisting as SD at
12 months. The remaining five lesions were true local
failures. Of the 13 lesions that did not show evidence of
PD, a CR was obtained in 11 lesions at a median of
3 months (range, 2–6), and SD was seen in the remaining
two tumors at last follow-up.
Conclusion Lesion enlargement following SRS for pediatric
intracranial tumors is common, and a proportion of patients
meeting requirements for PD at early radiographic follow-up
may later develop complete resolution of their lesions.
Physicians should be aware of these radiographic changes to
avoid unwarranted medical and surgical interventions.
Keywords Stereotactic radiosurgery (SRS).Brain tumor.
Pediatric.Magnetic resonance imaging (MRI)
Introduction
Intracranial malignancies are the most common solid
tumors of childhood and the second most common pediatric
cancer after hematologic malignancies [13]. The standard of
care for children greater than 3 years with central nervous
system (CNS) tumors is a multidisciplinary approach
combining surgery, radiotherapy, and chemotherapy [22].
Traditionally, conventional radiotherapy techniques have
been associated with modest efficacy yet carry a
significant risk for late treatment-related morbidity,
including endocrinopathies, osteopenia/osteonecrosis,
neurocognitive changes, growth alterations, and second
malignancies [30]. The clinical implementation of stereo-
tactic radiosurgery (SRS) for small volume lesions or as
adjuvant therapy following sub-total resections has several
potential advantages over traditional radiotherapy techni-
ques, including the ability to deliver higher doses with
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control and decreased treatment-related side effects.
Reports on SRS for pediatric intracranial tumors are still
immature but suggest better toxicity profiles over conven-
tional or whole brain radiation therapy techniques [2, 7, 9,
11, 12, 16, 17, 19, 21, 27] ,l i k e l ys e c o n d a r yt ol o w e r
volumes of normal brain tissue irradiation [20]. For these
reasons, SRS will likely have a more integral role in the
management of pediatric brain tumors in the near future.
One difficulty in treating patients with SRS is disease
surveillance. Following stereotactic radiosurgery (SRS) of
adult intracranial malignancies, it can be difficult to
distinguish between radiation effect and tumor progression
on magnetic resonance imaging (MRI) [6, 15, 24, 25].
Many physicians anticipate a near-complete response to
occur within 20 weeks of therapy, much like that seen for
metastases [24]. However, transient tumor edema or stable
disease following SRS can occur for several months [1, 15,
24, 25], leading to disagreements regarding the efficacy of
SRS therapy.
18F-flurodeoxyglucose positron emission
tomography (FDG-PET) [3],
11C-methionine PET [28,
29], single photon emission computed tomography
(SPECT) [18, 26], T1/T2 matching [15], and biopsy [14]
have all been studied to assess their clinical utility in
discriminating between radiation effect and disease pro-
gression; however, there is no universally accepted standard
regarding the use and interpretation of these tests. Many of
these tests are also not routinely available in all clinical
practices.
Since erroneous diagnosis of lesion progression can lead
to unwarranted interventions with little potential for benefit,
it is important to understand these imaging changes. In
particular, since the application of SRS for pediatric
intracranial tumors is a relatively new therapeutic approach,
few guidelines are available regarding the MRI changes
following therapy. As such, we have performed a review of
MRI scans on a series of children treated with SRS at our
institution in order to better clarify the natural course of
post-SRS intracranial lesions followed by MRI.
Methods
Institutional review board approval was obtained prior to
the initiation of this study. A retrospective review of patient
records was performed to identify all patients treated with
SRS for primary intracranial pediatric tumors. Twelve
patients at the University of California San Diego were
identified meeting this criteria. The clinical characteristics
of these patients are summarized in Table 1. Median patient
age was 12 (range 4–22). Largest tumor diameters ranged
from less than 5 to 31 mm.
The decision to treat with radiosurgery for primary,
recurrent, or residual disease was made based on history of
previous therapeutic interventions and/or consensus at
tumor board. Prescription dose delivered to the planning
target volume ranged from 14 to 30 Gy delivered in one to
five fractions (Table 1). Our technique for pediatric SRS
has been previously described [17]. All patients were
treated between September 2006 and October 2009.
All available MRIs were reviewed for each patient, and
lesions were grouped into the following categories based on
the revised Response Evaluation Criteria In Solid Tumors
version 1.1 [8]:
Table 1 Clinical characteristics
Patient Age Diagnosis No. of lesions Radiation Chemotherapy
a Surgery
b Follow-up time (months)
1 12 JPA recurrence 1 16 Gy×1 No Yes 32
2 4 JPA recurrence 1 6 Gy×5 No Yes 8
3 14 JPA residual 1 20 Gy×1 No Yes 31
4 12 JPA residual 1 20 Gy×1 No Yes 12
5 18 MB recurrence 3 20 Gy×1 Yes Yes 3
6 13 MB recurrence 4 10 Gy×2 Yes Yes 4
7 12 MB metastasis 1 14 Gy×1 Yes Yes 17
8 4 MB metastasis 4 6 Gy×5 Yes Yes 2
9 22 EM recurrence 1 6 Gy×5 No Yes 16
10 8 EM recurrence 1 20 Gy×1 Yes Yes 25
11 3 ATRT recurrence 2 20 Gy×1 Yes Yes 21
12 19 Pineocytoma 1 5 Gy×1 No Yes 39
Gy gray, MB medulloblastoma, JPA juvenile pilocytic astrocytoma, EM ependymoma, ATRT atypical rhabdoid teratoid tumor
aPrior to or concurrent with SRS
bPrior to SRS
400 Childs Nerv Syst (2011) 27:399–4061. Complete response (CR): near-complete disappearance
of target lesion
2. Partial response (PR): at least 30% decrease in sum of
target lesion diameters
3. Progressive disease (PD): at least 20% increase in sum
of target lesion diameters
4. Stable disease (SD): Insufficient change to qualify as
CR, PR, or PD
The determination of actual disease progression (local
failure) was based on clinical and imaging characteristics at
follow-up and discussion at tumor boards attended by
radiation, medical, and neurosurgical oncologists, as well as
pathologists and neuroradiologists. Where relevant, FDG-
PET, SPECT, and/or biopsy was performed to assist in the
discrimination between radiation effect and true disease
progression.
To compare lesion size on follow-up MRI scans to the
original planning isodose curves, follow-up MRI scans and
the planning CT were fused using a rigid auto-registration
tool (Varian Eclipse™) and subsequently manually verified.
Results
Median radiographic follow-up after SRS was 17 months
(range, 2–39). A total of 80 follow-up MRI scans were
reviewed with a median of eight per patient (range, 1–13).
During serial MRI evaluation, 11 lesions (52%) developed
a CR (without prior lesion growth large enough to qualify
as PD) at median time of 3 months (range, 2–6) following
SRS (Fig. 1; Table 2). Persistent SD without prior lesion
enlargement was seen in two lesions (10%) at the time of
analysis. The remaining eight lesions (38%) met criteria for
PD at a median of 6 months (range, 3–20). However, of
these, three (37%) represented transient tumor edema with
two (histology: juvenile pilocytic astrocytoma, atypical
rhabdoid teratoid tumor (ATRT)) later developing a CR at
a median of 15 months (Figs. 2 and 3) and one persisting as
SD at 12 months. Both patients who developed CR after
Fig. 1 Example of a complete response seen by MRI 2 months
following treatment with SRS for a medulloblastoma metastasis of the
right frontal lobe (patient 8). a Diagnostic MRI. b Follow-up MRI
scan at 2.2 months
Patient Diagnosis Imaging progression (months, following SRS) Outcome
1 JPA recurrence PD→PR (at 17)→CR (at 20) CR as of last f/u
2S D →PD (at 4)→Failed Local failure
3 JPA residual SD→PD (at 15)→Failed Local failure
4S D →PD (at 7)→SD (at 11) SD as of last f/u
5 MB recurrence CR (at 2) CR as of last f/u
5
5
6P R →CR (at 4)
6
6
6
7 MB metastasis SD→CR (at 6) CR as of last f/u
8 CR (at 2)
8
8 SD (at 2) SD as of last f/u
8
9 EM recurrence SD→PD (at 8)→Failed Local failure
10 PD (at 3)→Failed
11 ATRT recurrence SD→PD (at 4)→CR (at 10) CR as of last f/u
11 SD→PD (at 20)→Failed Local Failure
12 Pineocytoma CR (at 3) CR as of last f/u
Table 2 Radiographic response
of each lesion following SRS
SD stable disease, PD progres-
sive disease, CR complete
response, PR partial response,
MB medulloblastoma, JPA
juvenile pilocytic astrocytoma,
EM ependymoma, ATRT
atypical rhabdoid teratoid tumor,
f/u follow-up
Childs Nerv Syst (2011) 27:399–406 401initial PD were asymptomatic during the period of active
surveillance and have shown no evidence of local progres-
sion now at 22 and 32 months post-SRS. The remaining
five lesions were true local failures. The extent of transient
lesion enlargement in patient 11 (Tables 1 and 2) was found
to correspond with the 16 Gy isodose line (80% of
prescription dose) from the planning CT (Fig. 4).
Discussion
Approximately 66% of all children with intracranial tumors
will achieve long-term survival (greater than 5 years) [5].
Survivors of childhood brain malignancies are however
more likely to be functionally impaired and develop serious
long-term health problems, including endocrine deficien-
cies, physical disabilities, chronic fatigue, and learning
problems, than survivors of non-CNS malignancies [4, 10,
23]. This is in part related to the high morbidity associated
with medical, surgical, and radiotherapeutic interventions,
which have greater impact on the more vulnerable
developing CNS of children [30]. For this reason, mini-
mizing unwarranted therapeutics is essential for ensuring
high quality of life following tumor therapy. In this study,
we have attempted to characterize the observed MRI
changes following pediatric intracranial SRS in an effort
Fig. 2 Example of transient
tumor edema and sustained
contrast enhancement at several
time points following treatment
with SRS of a recurrent juvenile
pilocytic astrocytoma
(patient 1). a Diagnostic MRI.
b–i Follow-up MRI scans at
different time points
402 Childs Nerv Syst (2011) 27:399–406to elucidate the imaging characteristics of SRS-treated
lesions in order to better guide disease surveillance in these
patients. Overall, we have found that the response to SRS is
variable with a significant portion of lesions that initially
enlarge not representing true local failures. Improved
awareness of this phenomenon may reduce the number of
unnecessary interventions and improve long-term outcomes
of adult survivors of these childhood malignancies.
Complete resolution of lesions by MRI was common
following pediatric SRS. In Fig. 1, a CR within 3 months of
SRS is shown for a 4-year-old patient who received 30 Gy
in five fractions for a medulloblastoma metastasis. This
rapid and complete disappearance of the lesion occurred
frequently in our patient cohort, as over half of all treated
lesions developed a CR within 6 months of therapy.
Previous research on adult intracranial metastases has found
that a CR develops in 56% of lesions treated within
5 months of Gamma Knife radiosurgery [24], supporting
the findings in this study. As such, physicians should
recognize this as the predominant response pattern
following SRS.
Despite the favorable overall response to SRS, transient
lesion enlargement was found in roughly one third of
patients of who met requirements for PD at any time
following SRS. This problem is further exacerbated by the
timing of the CR after transient edema, which occurred
at a median of 15 months following therapy, long after
the 6-month window where most CR are seen. In the
example shown in Fig. 2, the patient developed persistent
homogenous ring enhancement for at least 17 months
following SRS. This patient was asymptomatic clinically
and had cystic changes indicative of radiation effect. As
such, active surveillance with serial MRI evaluations was
deemed appropriate.
Similarly, in Fig. 3, an example of transient lesion
enlargement is shown for a 4 year-old with two ATRT
tumors treated with single-fraction SRS to 20 Gy. The
patient developed transient swelling of one lesion with
heterogeneous contrast enhancement resembling recurrent
disease. As the patient was asymptomatic clinically and
further diagnostic studies (including FDG-PET and SPECT)
were equivocal, the patient was actively followed by serial
MRI scans. At 10 months post-SRS, she developed a CR
on MRI and remained asymptomatic. Figure 3 demonstrates
that at the time of maximal lesion size during MRI
surveillance, the 16 Gy line well-approximated the area of
enlargement, suggesting that the observed inflammatory
response could be explained by the treatment volume.
Although the complete extent of the edema is not contained
within the 16 Gy line in the axial view, some error is to be
Fig. 3 Example of transient
tumor enlargement with hetero-
geneous contrast enhancement
at several time points following
treatment with SRS for an ATRT
(patient 11). a Diagnostic MRI.
b–f Follow-up MRI scans at
different time points
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position during imaging. Regardless, it may be useful to
provide tumor boards or neuroradiologists with a planning
CT showing high-dose isodose curves in order to help
evaluate for disease progression during MRI evaluation.
Previous research has demonstrated a similar pattern of
lesion growth following SRS of adult intracranial malig-
nancies. Ross et al. examined the imaging characteristics of
30 malignant gliomas and 35 intracranial metastases and
found that 73% were larger a mean of 13 weeks following
SRS and 22% of metastatic lesions were larger a mean of
10 weeks following SRS [25]. FDG-PET was also found to
be unreliable in distinguishing radiation effect from tumor
progression. Peterson et al. performed serial MRI exami-
nations on 48 adult patients with 78 brain metastases and
reported transient lesion growth in five metastases [24]. The
literature describing imaging changes in pediatric patients is
more sparse. Bakardjiev et al. analyzed 28 children who
had been treated with SRS for low grade astrocytomas for
MRI changes that could mimic disease progression and
found that 43% of patients developed increased lesion size,
increased signal enhancement, cysts or cavitations, and an
increase in edema or mass effect on follow-up MRI [1].
They also reported that most patients with transient lesion
enlargement could be identified by a lack of clinical
symptoms. Thus, based on these studies, it appears that
lesion enlargement following SRS is common, and primary
intracranial tumors may have a higher rate of transient
radiation edema than metastases. This may be attributed to
the fact that metastases displace adjacent normal brain
tissue, whereas primary intracranial tumors are largely
infiltrative of brain parenchyma. Metastases may therefore
leave minimal residual tissue damage, whereas the ablation
of a primary tumor will likely leave a large cystic cavity
that evolves over time as cells die. Since the brain is a
devoid of lymphatics, it may take longer to clear cellular
debris than extracranial sites, leading to the development of
a prolonged inflammatory response.
There are several limitations to the current study. Our
sample size is small and composed of a heterogeneous
group of aggressive and benign primary pediatric brain
tumors. As such, it is difficult to draw definitive conclusions
for any one subgroup, as it is likely that each histological
subtype responds differently to SRS. However, little data is
available for MRI changes following pediatric SRS, and a
broad overview of multiple tumor types may therefore
provide an useful initial guideline for disease surveillance
in these patients. A prospective evaluation with a larger
well-defined cohort is warranted, particularly examining
factors predictive of transient lesion enlargement.
In summary, we have followed the MRI changes of 21
pediatric brain tumors treated with SRS in an effort to
characterize the evolution of imaging responses following
therapy. The predominant pattern of change was a CR seen
within 6 months of therapy. However, one third of lesions
that showed signs of growth did not ultimately progress
with one lesion developing a CR greater than 17 months
following SRS. A lack of clinical symptoms and cystic
change helped to distinguish transient radiation effect from
disease progression. High isodose curves, particularly the
Fig. 4 Extent of tumor enlarge-
ment corresponding to isodose
curves on planning CT. a Plan-
ning target volume on the original
planning CT for a patient with an
ATRT (patient 11). b Follow-up
MRI scan at 6 months post-SRS
with extensive edema. c The
same MRI scan as in b after
registering it with the original
planning CT and displaying
isodose curves. d–f Axial,
coronal, and sagittal views of the
6-month follow-up MRI
registered with the planning CT
and displaying the 16 Gy line
(80% isodose curve)
404 Childs Nerv Syst (2011) 27:399–40616 Gy line, were found to encompass the extent of lesion
edema, and may be useful to neuroradiologists or tumor
boards when evaluating treatment response during serial
MRI examinations.
Conflicts of interest notification Arno J. Mundt and Kevin T.
Murphy have received honorariums from Varian Medical Systems for
giving lectures. The Center for Advanced Radiotherapy Technologies
receives research funding from Varian Medical Systems.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Bakardjiev AI, Barnes PD, Goumnerova LC, Black PM, Scott
RM, Pomeroy SL, Billett A, Loeffler JS, Tarbell NJ (1996)
Magnetic resonance imaging changes after stereotactic radiation
therapy for childhood low grade astrocytoma. Cancer 78:864–873
2. Baumann GS, Wara WM, Larson DA, Sneed PK, Gutin PH,
Ciricillo SF, McDermott MW, Park E, Stalpers LJ, Verhey LJ,
Smith V, Petti PL, Edwards MS (1996) Gamma knife radiosurgery
in children. Pediatr Neurosurg 24:193–201
3. Belohlavek O, Simonova G, Kantorova I, Novotny J Jr, Liscak R
(2003) Brain metastases after stereotactic radiosurgery using the
Leksell gamma knife: can FDG PET help to differentiate radionecrosis
from tumour progression? Eur J Nucl Med Mol Imaging 30:96–100
4. Bhat SR, Goodwin TL, Burwinkle TM, Lansdale MF, Dahl GV,
Huhn SL, Gibbs IC, Donaldson SS, Rosenblum RK, Varni JW,
Fisher PG (2005) Profile of daily life in children with brain
tumors: an assessment of health-related quality of life. J Clin
Oncol 23:5493–5500
5. CBTRUS (2007) Statistical Report: Primary Brain Tumors in the
United States, 1998–2002. Central Brain Tumor Registry of the
United States; wwwcbtrusorg
6. Dequesada IM, Quisling RG, Yachnis A, Friedman WA (2008)
Can standard magnetic resonance imaging reliably distinguish
recurrent tumor from radiation necrosis after radiosurgery for
brain metastases? A radiographic-pathological study. Neurosurgery
63:898–903, discussion 904
7. Eder HG, Leber KA, Eustacchio S, Pendl G (2001) The role of
gamma knife radiosurgery in children. Childs Nerv Syst 17:341–
346, discussion 347
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent
D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M,
Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D,
Verweij J (2009) New response evaluation criteria in solid
tumours: revised RECIST guideline (version 1.1). Eur J Cancer
45:228–247
9. Flannery T, Kano H, Martin JJ, Niranjan A, Flickinger JC,
Lunsford LD, Kondziolka D (2009) Boost radiosurgery as a
strategy after failure of initial management of pediatric primitive
neuroectodermal tumors. J Neurosurg Pediatr 3:205–210
10. Geenen MM, Cardous-Ubbink MC, Kremer LC, van den Bos C,
van der Pal HJ, Heinen RC, Jaspers MW, Koning CC,
Oldenburger F, Langeveld NE, Hart AA, Bakker PJ, Caron
HN, van Leeuwen FE (2007) Medical assessment of adverse
health outcomes in long-term survivors of childhood cancer.
JAMA 297:2705–2715
11. Giller CA, Berger BD, Pistenmaa DA, Sklar F, Weprin B, Shapiro
K, Winick N, Mulne AF, Delp JL, Gilio JP, Gall KP, Dicke KA,
Swift D, Sacco D, Harris-Henderson K, Bowers D (2005)
Robotically guided radiosurgery for children. Pediatr Blood
Cancer 45:304–310
12. Grabb PA, Lunsford LD, Albright AL, Kondziolka D, Flickinger
JC (1996) Stereotactic radiosurgery for glial neoplasms of
childhood. Neurosurgery 38:696–701, discussion 701–692
13. Gurney JG, Smith MA, Bunin GR (1999) CNS and Miscellaneous
Intracranial and Intraspinal Neoplasms (Chapter in: Cancer
Incidence and Survival among Children and Adolescents: United
States SEER Program 1975–1995). National Cancer Institute,
SEER Program, NIH Pub. No. 99-4649, Bethesda, MD
14. Harris OA, Adler JR (1996) Analysis of the proliferative potential
of residual tumor after radiosurgery for intraparenchymal brain
metastases. J Neurosurg 85:667–671
15. Kano H, Kondziolka D, Lobato-Polo J, Zorro O, Flickinger JC,
Lunsford LD (2010) T1/T2 matching to differentiate tumor
growth from radiation effects after stereotactic radiosurgery.
Neurosurgery 66:486–491, discussion 491–482
16. Kano H, Niranjan A, Kondziolka D, Flickinger JC, Pollack IF,
Jakacki RI, Lunsford LD (2009) Stereotactic radiosurgery for
pilocytic astrocytomas part 2: outcomes in pediatric patients. J
Neurooncol 95:219–229
17. Keshavarzi S, Meltzer H, Ben-Haim S, Newman CB, Lawson JD,
Levy ML, Murphy K (2009) Initial clinical experience with
frameless optically guided stereotactic radiosurgery/radiotherapy
in pediatric patients. Childs Nerv Syst 25:837–844
18. Kimura T, Sako K, Tanaka K, Gotoh T, Yoshida H, Aburano T,
Tanaka T, Arai H, Nakada T (2004) Evaluation of the response of
metastatic brain tumors to stereotactic radiosurgery by proton
magnetic resonance spectroscopy, 201TlCl single-photon emission
computerized tomography, and gadolinium-enhanced magnetic
resonance imaging. J Neurosurg 100:835–841
19. Kondziolka D, Lunsford LD, Flickinger JC (1990) Stereotactic
radiosurgery in children andadolescents.PediatrNeurosurg16:219–221
20. Lawrence YR, Li XA, el Naqa I, Han CA, Marks LB, Merchant
TE, Dicker AP (2010) Radiation dose-volume effects in the brain.
Int J Radiat Oncol Biol Phys 76:S20–S27
21. Mansur DB, Rubin JB, Kidd EA, King AA, Hollander AS, Smyth
MD, Limbrick DD, Park TS, Leonard JR (2010) Radiation
Therapy for Pilocytic Astrocytomas of Childhood. Int J Radiat
Oncol Biol Phys (in press)
22. Mueller S, Chang S (2009) Pediatric brain tumors: current
treatment strategies and future therapeutic approaches. Neuro-
therapeutics 6:570–586
23. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson
MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-
Lottick NS, Schwartz CL, Leisenring W, Robison LL (2006)
Chronic health conditions in adult survivors of childhood cancer.
N Engl J Med 355:1572–1582
24. PetersonAM,MeltzerCC,EvansonEJ,FlickingerJC,KondziolkaD
(1999) MR imaging response of brain metastases after gamma knife
stereotactic radiosurgery. Radiology 211:807–814
25. Ross DA,SandlerHM, BalterJM,Hayman JA, Archer PG, Auer DL
(2002) Imaging changes after stereotactic radiosurgery of primary
and secondary malignant brain tumors. J Neurooncol 56:175–181
26. Schwartz RB, Holman BL, Polak JF, Garada BM, Schwartz MS,
Folkerth R, Carvalho PA, Loeffler JS, Shrieve DC, Black PM,
Alexander E 3rd (1998) Dual-isotope single-photon emission
computerized tomography scanning in patients with glioblastoma
multiforme: association with patient survival and histopathological
characteristics of tumor after high-dose radiotherapy. J Neurosurg
89:60–68
Childs Nerv Syst (2011) 27:399–406 40527. Somaza SC, Kondziolka D, Lunsford LD, Flickinger JC,
Bissonette DJ, Albright AL (1996) Early outcomes after stereo-
tactic radiosurgery for growing pilocytic astrocytomas in children.
Pediatr Neurosurg 25:109–115
28. Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S,
Takami T, Ohata K (2008) Diagnostic accuracy of 11C-
methionine PET for differentiation of recurrent brain tumors from
radiation necrosis after radiotherapy. J Nucl Med 49:694–699
29. Tsuyuguchi N, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Takami
T, Otsuka Y, Sakamoto S, Ohata K, Goto T, Hara M (2003)
Methionine positron emission tomography of recurrent metastatic
brain tumor and radiation necrosis after stereotactic radiosurgery:
is a differential diagnosis possible? J Neurosurg 98:1056–1064
30. Turner CD, Rey-Casserly C, Liptak CC, Chordas C (2009) Late
effects of therapy for pediatric brain tumor survivors. J Child
Neurol 24:1455–1463
406 Childs Nerv Syst (2011) 27:399–406